BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32236609)

  • 1. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
    Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
    Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
    Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
    Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of RNF43 Genetic Alterations With BRAF
    Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
    JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
    Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
    J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
    Lai C; Sun W; Wang X; Xu X; Li M; Huang D; Xu E; Lai M; Zhang H
    Pathol Res Pract; 2019 Aug; 215(8):152453. PubMed ID: 31122752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.
    Siraj AK; Bu R; Masoodi T; Parvathareddy SK; Iqbal K; Al-Haqawi W; Al-Dossari H; Azam S; Qadri Z; Annaiyappanaidu P; Al-Dayel F; Al-Kuraya KS
    Sci Rep; 2022 Jul; 12(1):13098. PubMed ID: 35907983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
    Yan HHN; Lai JCW; Ho SL; Leung WK; Law WL; Lee JFY; Chan AKW; Tsui WY; Chan ASY; Lee BCH; Yue SSK; Man AHY; Clevers H; Yuen ST; Leung SY
    Gut; 2017 Sep; 66(9):1645-1656. PubMed ID: 27329244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
    Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
    J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
    Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
    J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
    Seeber A; Battaglin F; Zimmer K; Kocher F; Baca Y; Xiu J; Spizzo G; Novotny-Diermayr V; Rieder D; Puccini A; Swensen J; Ellis M; Goldberg RM; Grothey A; Shields AF; Marshall JL; Weinberg BA; Sackstein PE; Lim KH; Tan GS; Nabhan C; Korn WM; Amann A; Trajanoski Z; Berger MD; Lou E; Wolf D; Lenz HJ
    Clin Cancer Res; 2022 May; 28(9):1863-1870. PubMed ID: 35254413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF
    Elez E; Ros J; Fernández J; Villacampa G; Moreno-Cárdenas AB; Arenillas C; Bernatowicz K; Comas R; Li S; Kodack DP; Fasani R; Garcia A; Gonzalo-Ruiz J; Piris-Gimenez A; Nuciforo P; Kerr G; Intini R; Montagna A; Germani MM; Randon G; Vivancos A; Smits R; Graus D; Perez-Lopez R; Cremolini C; Lonardi S; Pietrantonio F; Dienstmann R; Tabernero J; Toledo RA
    Nat Med; 2022 Oct; 28(10):2162-2170. PubMed ID: 36097219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
    Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
    Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
    Roma C; Rachiglio AM; Pasquale R; Fenizia F; Iannaccone A; Tatangelo F; Antinolfi G; Parrella P; Graziano P; Sabatino L; Colantuoni V; Botti G; Maiello E; Normanno N
    Cancer Biol Ther; 2016 Aug; 17(8):840-8. PubMed ID: 27261210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer.
    Shimada Y; Kameyama H; Nagahashi M; Ichikawa H; Muneoka Y; Yagi R; Tajima Y; Okamura T; Nakano M; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Hayashida T; Takaishi H; Kitagawa Y; Oki E; Konishi T; Ishida F; Kudo SE; Ring JE; Protopopov A; Lyle S; Ling Y; Okuda S; Ishikawa T; Akazawa K; Takabe K; Wakai T
    Oncotarget; 2017 Nov; 8(55):93567-93579. PubMed ID: 29212173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.